FDA Adds 3 More Chinese Drugmakers to GMP, Refusal to Inspect Import Alerts

International Pharmaceutical Regulatory Monitor
A A
The list of Chinese pharmaceutical companies in the FDA’s crosshairs keeps on growing, with the agency hitting two drugmakers for GMP violations and another for refusing an inspection.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor